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survival, local control or toxicity profile. Epidemiological data was 
searched to determine the proportion of new cases of cancer with 
each indication. Patient preference data were included for breast and 
prostate cancers. Indications and epidemiological data were reviewed 
by a court of external reviewers. Univariate and Monte Carlo 
simulations were used in sensitivity analysis. 
Results: Over 600 papers and guidelines were reviewed for 20 cancer 
sites. The proportions of cancer types had changed markedly over 10 
years. Prostate cancer increased from 12% of all cancers to 18%. The 
guidelines suggest that 48.6% of new cases of cancer have an 
indication for radiotherapy (with or without chemotherapy) at least 
once in the course of their illness. The range was from 0% for liver 
cancer to 94% for vaginal cancer. 9.1% of cases had an indication for 
synchronous chemoradiotherapy. 
Conclusions: The small decrease in optimum radiotherapy utilisation 
rate was mostly due to changes in the proportions of cancer in the 
population and the removal of a small numberof indications for 
radiotherapy.  
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Purpose/Objective: Documenting key parameters for the activity, 
utilization and infrastructure of radiotherapy in Europe is an impor-
tant part of HERO - the ESTRO Health Economics in Radiation Oncology 
project [1]. HERO has the overall aim to develop a knowledge base of 
the provision of radiotherapy in Europe and build a model for health 
economic evaluation of radiation treatments at the European level. 
The aim of the current report is to describe the initial analysis of a 
pan-European survey of radiotherapy activity and infrastructure. 
Materials and Methods: Contact persons representing the national 
societies within radiation oncology in 42 European countries were 
identified from the ESTRO database and personal contacts. The con-
tact persons were asked to respond to an 84-item web-based ques-
tionnaire detailing epidemiology (population, cancer types and cases 
per year), radiotherapy activity (number of courses, number of pa-
tients treated), infrastructure (departments and technology), staffing 
and economics (public/private facilities, type of reimbursement), all 
on a national level. By December 2012, a total of 29 European coun-
tries have entered their data. 
Results: A large variation between countries was found for most 
parameters studied. Between countries the proportion of annual 
patients treated with radiotherapy relative to all new cancer cases 
varied from 20% to 55% (median 39%); the number of MV machines per 
million inhabitants from 1.25 to 9.62 (median 5.29) and the average 
number of MV machines per department from 0.8 to 8.0 (median 2.0). 
The average number of patients treated per year per MV machine 
varied from 205 to 862 (median 325), per radiation oncologist (89 to 
266; median 167), per radiation physicist (121 to 435; median 263), 
and per radiation therapist (23 to 595; median 101). 
Conclusions: The initial results of this survey have documented an 
enormous heterogeneity, in the order of a factor of 3-5, in all key 
parameters related to activity, utilization, infrastructure and staffing 
of radiotherapy in Europe. Radiotherapy seemed to be underutilized in 
most countries when compared to evidence based data from CCORE 
[2], although there has been a positive evolution in availability and 
infrastructure compared to the earlier studies [3,4]; the European 
average number of MV machines per million inhabitants and per 
department is now in line with QUARTS recommendations [4]. The 
data will be further analyzed in the context of the ESTRO HERO 
project, in collaboration with the national societies and the Interna-
tional Atomic Energy Agency. 
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Purpose/Objective: ESTRO has launched the Health Economics in 
Radiation Oncology (HERO) project to develop a knowledge base and a 
model for health economic evaluation of radiotherapy (1). In this 
framework, the need for radiotherapy will be assessed in order to 
explore the optimum radiotherapy utilization in Europe. The percen-
tage of new cancer patients who require radiotherapy relative to the 
total number of cancer patients (Attributable Radiotherapy Percen-
tage, ARP) is one of the usual measures for planning purposes of 
radiotherapy equipment and staffing. The objective of this work was 
to assess the variability of ARP according to the differences in propor-
tional incidence and in stage at diagnosis by country in Europe. 
Materials and Methods: Decision trees from the Australian CCORE-
projectwere used to assess the percentage of patients requiring 
evidence-basedradiotherapy (2). The original incidence data were 
substituted with theproportional distribution of cancers in different 
European countries, based onincidence data for 2008 from Globocan 
(www.iarc.fr). Available data on population-based stage at diagnosis 
were used for head and neck, lung, breast, prostate and rectal cancer 
in selected countries, used for exploratory purposes. The analysis was 
carried out with TreeAge software. 
Results: The range of values of ARP among European countries varied 
from 52% to 57% of new cancer cases. Stage at diagnosis also contri-
buted to the variability of ARP estimates with a range from 2% in 
breast cancer to 15% in rectal cancer. Most relevant factors influen-
cing the ranges of values observed were due to the percentage of 
cases diagnosed at earlystage with surgery as the only treatment in 
rectal cancer; and the important variability in the incidence by coun-
try of head and neck cancer and prostate.These estimates were 
evidence based and did not take into account clinical problems such 
as comorbidity that could influence the decision for treatment. Also, 
the number of patients that could require retreatment is not included 
in the estimate. Both factors could modify significantly the final ARP 
percentage of incidence cases for planning radiotherapy in a specific 
country. 
Conclusions: ARP is a useful indicator for assessing the needs for 
radiotherapy; however, national differences in the incidence of 
cancer and stage at diagnosis should be taken into account in order to 
make a more realistic estimate for planning purposes. The range 
observed betweencountries and tumour stages could translate into a 
significant change in the number of facilities required. 
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Purpose/Objective: Delaney et al (2003) estimated that more than 
half of all cancer patients should receive radiotherapy at some point 
during the course of the disease. Actual Radiotherapy Utilization 
(RTU) rates are usually lower than the optimal rates 
Our objectives were: 
